<b>Date of Acquisition</b><tr>
<td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Dieter W. Priess Medtechnik</font></p></td>
<td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td>
<td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">February7, 1996</font></td></tr><td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Dieter W. Priess Medtechnik</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Dieter W. Priess Medtechnik</font></p><td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td><td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">February7, 1996</font></td><tr>
<td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Premium Medical SARL</font></p></td>
<td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td>
<td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">June12, 1996</font></td></tr><td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Premium Medical SARL</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Premium Medical SARL</font></p><td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td><td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">June12, 1996</font></td><tr>
<td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Innovmedics Pte Ltd</font></p></td>
<td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td>
<td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">November1, 1997</font></td></tr><td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Innovmedics Pte Ltd</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Innovmedics Pte Ltd</font></p><td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td><td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">November1, 1997</font></td><tr>
<td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">EINAR Egnell AB</font></p></td>
<td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td>
<td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">January31, 2000</font></td></tr><td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">EINAR Egnell AB</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">EINAR Egnell AB</font></p><td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td><td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">January31, 2000</font></td><tr>
<td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">MAP Medizin Technologie GmbH</font></p></td>
<td style="BORDER-LEFT:1px solid #000000" valign="bottom"><font size="1"></font></td>
<td style="BORDER-RIGHT:1px solid #000000; padding-right:8px" valign="bottom"><font face="Times New Roman" size="2">February16, 2001</font></td></tr><td style="BORDER-LEFT:1px solid #000000; padding-left:8px" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">MAP Medizin Technologie GmbH</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">MAP Medizin Technologie GmbH</font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>Business Acquisitions </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Fiscal year ended June30, 2007 </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Western Medical Marketing (WMM).</b>On October4, 2006 we acquired the business assets of WMM, a distribution
business operating in the Pacific Northwest region of the U.S. for a total cash consideration of $0.3 million. The acquisition has been accounted as a purchase and accordingly the results of operations of WMM have been included in our consolidated
financial statements since October4, 2006. An amount of $0.3 million, representing the excess of the purchase price over the fair value of the identifiable net assets acquired, has been recorded as goodwill. We have completed our purchase
price allocation at June30, 2007. </font></p><b>Western Medical Marketing (WMM).</b><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Fiscal year ended
June30, 2006 </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>PolarMed Holding AS
(PolarMed).</b>As disclosed in our consolidated financial statements and Form 10-K for the year ended June30, 2006, we acquired 100% of the outstanding stock of </font>
</p><font face="Times New Roman" size="2"><b>PolarMed Holding AS
(PolarMed).</b>As disclosed in our consolidated financial statements and Form 10-K for the year ended June30, 2006, we acquired 100% of the outstanding stock of </font><b>PolarMed Holding AS
(PolarMed).</b><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2">- 31 - </font></p><p style="page-break-before:always">
</p><hr align="CENTER" color="#999999" size="3" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p style="margin-top:0px;margin-bottom:0px; margin-left:9%">
<font face="Times New Roman" size="2">PolarMed, the holding company for PolarMed AS and its affiliates, on December1, 2005, for net cash consideration of $6.5 million. This was comprised of
$6.8 million in consideration less $0.3 million of cash acquired. Additionally, as part of the acquisition, we assumed debt of $1.5 million. Under the purchase agreement, we may also be required to make additional future payments of up to $3.0
million based on the achievement of certain performance milestones following the acquisition through December31, 2008. Of the $3.0 million in potential future payments included within the purchase agreement, $1.0 million was paid during the
year ended June30, 2007 as a result of the successful achievement of a performance milestone. This additional payment increased the total acquisition consideration to $7.8 million from $6.8 million and increased the amount recorded as goodwill
to $5.4 million from $4.4 million. </font></p><font face="Times New Roman" size="2">PolarMed, the holding company for PolarMed AS and its affiliates, on December1, 2005, for net cash consideration of $6.5 million. This was comprised of
$6.8 million in consideration less $0.3 million of cash acquired. Additionally, as part of the acquisition, we assumed debt of $1.5 million. Under the purchase agreement, we may also be required to make additional future payments of up to $3.0
million based on the achievement of certain performance milestones following the acquisition through December31, 2008. Of the $3.0 million in potential future payments included within the purchase agreement, $1.0 million was paid during the
year ended June30, 2007 as a result of the successful achievement of a performance milestone. This additional payment increased the total acquisition consideration to $7.8 million from $6.8 million and increased the amount recorded as goodwill
to $5.4 million from $4.4 million. </font><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Pulmomed
Medizinisch-Technische Gerte GmbH (Pulmomed).</b>As disclosed in our consolidated financial statements and Form 10-K for the year ended June30, 2006, we acquired 100% of the outstanding stock of
Pulmomed on July1, 2005 for net cash consideration of $2.5 million, including acquisition costs. Additionally, as part of the acquisition, we assumed debt of $1.0 million. Under the purchase agreement, we may also be required to make
additional future payments of up to $0.9 million based on the achievement of certain performance milestones following the acquisition through June30, 2007. Of the $0.9 million in potential future payments included within the purchase
agreement, $0.3 million was paid during the year ended June30, 2007 as a result of the successful achievement of a performance milestone. This additional payment was accrued at June30, 2006, which increased the total acquisition
consideration to $2.8 million from $2.5 million and increased the amount recorded as goodwill by $0.3 million to $2.1 million. </font></p><b>Pulmomed
Medizinisch-Technische Gerte GmbH (Pulmomed).</b><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Fiscal year ended June30, 2005 </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Saime SAS (Saime).</b>We acquired 100% of the outstanding stock of Financiere ACE SAS, the holding company for
Saime and its affiliates, on May19, 2005, for net cash consideration of $40.6 million. This consisted of $51.1 million in consideration, including acquisition costs, less $10.5 million of cash acquired. An amount of $64.8 million, representing
the excess of the purchase price over the fair value of the identifiable net assets acquired, has been recorded as goodwill. </font></p><b>Saime SAS (Saime).</b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Hoefner Medizintechnick GmbH (Hoefner).</b>We acquired 100% of the outstanding stock of Hoefner on
February14, 2005, for net cash consideration of $8.2 million. This consisted of the $10.7 million in total consideration, including acquisition costs, less $2.5 million of cash acquired. Under the purchase agreement, additional future payments
of up to $0.9 million were possible based on the achievement of certain performance milestones following the acquisition through December31, 2006. Of the $0.9 million in potential future payments, $0.6 million was paid during fiscal 2006. The
remaining $0.3 million of the $0.9 million was paid during the year ended June30, 2007 as a result of the successful achievement of a performance milestone. This additional payment increased the total acquisition consideration to $11.6 million
and goodwill to $9.1 million. </font></p><b>Hoefner Medizintechnick GmbH (Hoefner).</b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Resprecare BV
(Resprecare).</b>On December1, 2004, we acquired substantially all the assets of Resprecare BV, our Dutch distributor, for initial consideration of $5.9 million in cash, including acquisition costs. Under
the purchase agreement, we potentially were also required to make up to $1.4 million of additional future payments based on the achievement of certain milestones. Of these potential additional payments, $0.6 million was paid in January 2005 and a
further $0.7 million was paid in January 2006 as a result of the integration of the Dutch subsidiary of our subsidiary MAP Medizin-Technologie GmbH, or MAP, with the newly-acquired Resprecare business. An amount of $4.4 million, representing the
excess of the purchase price over the fair value of identifiable net assets acquired of $2.8 million, was recorded as goodwill. </font></p><b>Resprecare BV
(Resprecare).</b><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2">- 32 - </font></p><p style="page-break-before:always">
</p><hr align="CENTER" color="#999999" size="3" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>In-Process Research and Development Charge (IPR&amp;D) </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2">On acquisition of Saime in May 2005, we recognized as an expense a charge of
$5.3 million with respect to IPR&amp;D programs under active development by Saime that, at date of acquisition, had not reached technological feasibility and had no alternative future use. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2"><b>Stock-Based Compensation Costs </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2">We have granted stock options to personnel, including officers and
directors, under our 1995 Option Plan (the 1995 Plan), our 1997 Equity Participation Plan (the 1997 Plan) and our 2006 Incentive Award Plan, as amended (the 2006 Plan and together with the 1995 Plan and the 1997
Plan, the Plans). These options have expiration dates of seven or ten years from the date of grant and vest over three or four years. We granted these options with the exercise price equal to the market value as determined at the date of
grant. We have also offered to our personnel, including officers and directors, the right to purchase shares of our common stock at a discount pursuant to our employee stock purchase plan (ESPP). </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:9%"><font face="Times New Roman" size="2">As of July1, 2005, we adopted SFAS No.123(R) using the modified
prospective method, which requires measurement of compensation expense of all stock-based awards at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Under this method, the
provisions of SFAS No.123(R) apply to all awards granted or modified after the date of adoption. In addition, the unrecognized expense of awards not yet vested at the date of adoption, determined under the original provisions of SFAS No.123,
Accounting for Stock Based Compensation (SFAS 123), shall be recognized in net income in the periods after adoption. The fair value of stock options is determined using the Black-Scholes valuation model. Such value is
recognized as expense over the service period, using the graded-attribution method for stock-based awards granted prior to July1, 2005 and the straight-line method for stock-based awards granted after July1, 2005. </font></p>